Join Paid Research Studies for Chronic Illness in Australia

Effect of an Eccentric Exercise Program on Quality of Life and Function in People With Chronic Heart Failure.

Condition: Chronic Heart Failure
Interventions: Other: walking and light weights; Other: eccentric aerobic exercise; Other: concentric aerobic exercise
Sponsors: La Trobe University; Northern Hospital, Australia
Recruiting
A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children

Condition: Respiratory Syncytial Virus Infections
Interventions: Drug: MEDI8897; Drug: Palivizumab
Sponsor: MedImmune LLC
Not yet recruiting
A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis

Condition: Giant Cell Arteritis (GCA)
Interventions: Drug: Upadacitinib; Drug: Corticosteroid (CS); Other: Placebo
Sponsor: AbbVie
Recruiting
A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy

Condition: Psoriatic Arthritis
Interventions: Biological: placebo for rizankizumab; Biological: risankizumab
Sponsor: AbbVie
Recruiting
Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma

Conditions: Recurrent Neuroblastoma; Stage 2A Neuroblastoma; Stage 2B Neuroblastoma; Stage 3 Neuroblastoma; Stage 4 Neuroblastoma; Stage 4S Neuroblastoma
Interventions: Other: Cytology Specimen Collection Procedure; Other: Laboratory Biomarker Analysis; Other: Quality-of-Life Assessment
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting
A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy

Condition: Crohn's Disease
Interventions: Other: Matching placebo for upadacitinib; Drug: upadacitinib
Sponsor: AbbVie
Recruiting
Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)

Condition: Ankylosing Spondylitis
Intervention: Drug: Tofacitinib
Sponsor: Pfizer
Recruiting
A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood Transfusion (Cadenza Study)

Condition: Agglutinin Disease, Cold
Interventions: Drug: Sutimlimab; Drug: Placebo
Sponsor: Bioverativ Therapeutics Inc.
Recruiting
A Study of the Efficacy and Safety of Upadacitnib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies

Condition: Crohn's Disease
Interventions: Drug: Upadacitinib; Drug: Placebo for Upadacitinib
Sponsor: AbbVie
Recruiting
A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)

Condition: Psoriatic Arthritis
Interventions: Biological: placebo for rizankizumab; Biological: risankizumab
Sponsor: AbbVie
Recruiting
A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission

Condition: Acute Myeloid Leukemia
Interventions: Drug: Idasanutlin; Drug: Cytarabine; Drug: Daunorubicin; Procedure: Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)
Sponsor: Hoffmann-La Roche
Recruiting
A Study of the Efficacy and Safety of Risankizumab in Subjects With Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991; or Completed M15-989

Condition: Crohn's Disease
Interventions: Drug: placebo for risankizumab SC; Drug: risankizumab IV; Drug: placebo for risankizumab IV; Drug: risankizumab SC
Sponsor: AbbVie
Recruiting
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus

Condition: Systemic Lupus Erythematosus
Interventions: Drug: Baricitinib; Drug: Placebo
Sponsors: Eli Lilly and Company; Incyte Corporation
Recruiting
JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis

Condition: Atopic Dermatitis
Interventions: Drug: Placebo; Drug: PF-04965842; Drug: PF04965842
Sponsor: Pfizer
Recruiting
Observational Study of Obstructive Lung Disease (NOVELTY)

Conditions: Asthma; COPD; Chronic Obstructive Pulmonary Disease
Interventions: Procedure: Blood draw; Procedure: Urine; Procedure: Lung function measurements; Procedure: Fractional Exhaled Nitric Oxide (FENO)
Sponsors: AstraZeneca; Parexel
Recruiting

Join Paid Research Studies for Chronic Illness in Australia

Welcome to Paid Research Studies